MSF wins Sovaldi battle in Ukraine as Gilead relents

12 December 2017

Médecins Sans Frontières (MSF) hopes the introduction of generic versions of Sovaldi (sofosbuvir) in Ukraine will bring savings of more than 86%.

The medical humanitarian organization led the fight for generic versions of the hepatitis C treatment to be registered and sold in the eastern European country, a battle that it has now won after US biotech firm Gilead Sciences (Nasdaq: GILD) extended its voluntary license.

Sofosbuvir is the backbone of hepatitis C treatment and cheaper versions of the lifesaving drug are needed to ensure access to treatment in countries such as Ukraine, including for patients who are co-infected with HIV, says MSF.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK